MAPT and dementia: Regarding prognosis, recent work has shown that plasma biomarkers for tau pathology are associated with future cognitive decline,46 and in combination with brief in‐clinic pen‐and‐paper cognitive tests, can identify MCI patients who are likely to progress toward dementia.47